Table 4 Outcomes of KRAS/RAS testing in Round 3 of the medical records review study
Outcome | No. of patients (%) | ||
|---|---|---|---|
All patients | RAS(N = 109) | KRAS(N = 22) | Total(N = 131) |
Tested for mutation status prior to first dose of panitumumab | 109 (100.0) | 22 (100.0) | 131 (100.0) |
Wild-type mutation status test result confirmed prior to first dose of panitumumab | 109 (100.0) | 22 (100.0) | 131 (100.0) |
Subset of patients treated with concurrent oxaliplatin-containing therapy | RAS (N = 64) | KRAS (N = 7) | Total (N = 71) |
Tested for mutation status prior to first dose of panitumumab | 64 (100.0) | 7 (100.0) | 71 (100.0) |
Wild-type mutation status test result confirmed prior to first dose of panitumumab | 64 (100.0) | 7 (100.0) | 71 (100.0) |